Interestingly, EZH2 acts inversely in ER-positive luminal breast cancer cells and suppresses the expression of NF-κB target genes by interacting with ER and directing repressive histone methylation to its promoters (Lee et al., 2011). Here, EZH2 is linked to breast cancer.